A novel inhibitor to prevent uncontrolled bleedings in anticoagulant users
DOAC-STOP aims to develop PseudoXa, a biological for the instantaneous restoration of blood clotting activity in patients with major bleedings as a result of blood thinners. PseudoXa will be produced and the preclinical efficacy, pharmacokinetics (PK), and toxicity (TOX) of PseudoXa will be determined in vitro and in vivo. The end result will be a completed preclinical study dossier for PseudoXa. After the project, clinical phase development will be initiated.
2 674 400.00€
Pharmaceutical Products / Drugs